Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609803 | 1.00 | FAAH (0.48) | FAAHNR1D1NPC1ALDH1A1MAPT | |
| SCHEMBL1990628 | 0.81 | FAAH (0.52) | FAAHNR1D1NPC1MAPTHTT | |
| SCHEMBL1990630 | 0.81 | FAAH (0.52) | FAAHNR1D1NPC1MAPTHTT | |
| SCHEMBL20015397 | 0.80 | FAAH (0.66) | FAAHNR1D1ALDH1A1HTTSTS | |
| SCHEMBL12614537 | 0.79 | FAAH (0.48) | FAAHNR1D1HTTSTSGPR119 | |
| SCHEMBL4156081 | 0.77 | MAOB (0.49) | FAAHGPR119 | |
| SCHEMBL20015305 | 0.76 | NPC1 (0.62) | FAAHNPC1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1990217 | 0.75 | SMN1; SMN2 (0.46) | FAAHNR1D1MAPTRAB9AL3MBTL1 | |
| SCHEMBL1990216 | 0.75 | SMN1; SMN2 (0.46) | FAAHNR1D1MAPTRAB9AL3MBTL1 | |
| SCHEMBL1991147 | 0.75 | FAAH (0.46) | FAAHNR1D1NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688870-B1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-8802673-B2 | Heterocyclic amine derivatives | Hoffmann-La Roche Inc (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | TAAR1, TAAR5, MTNR1A | FAAH 300/4885NR1D1 116/4885NPC1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.